HOOKIPA Pharma (HOOK) Stock Overview
A clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
HOOK Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
HOOKIPA Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.19 |
| 52 Week High | US$1.77 |
| 52 Week Low | US$0.81 |
| Beta | 0.83 |
| 1 Month Change | 3.48% |
| 3 Month Change | 19.00% |
| 1 Year Change | -23.72% |
| 3 Year Change | -91.38% |
| 5 Year Change | -99.29% |
| Change since IPO | -99.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| HOOK | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.8% | -1.6% | -0.3% |
| 1Y | -23.7% | 34.3% | 24.0% |
Return vs Industry: HOOK underperformed the US Biotechs industry which returned 34.4% over the past year.
Return vs Market: HOOK underperformed the US Market which returned 24.4% over the past year.
Price Volatility
| HOOK volatility | |
|---|---|
| HOOK Average Weekly Movement | 3.7% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: HOOK has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: HOOK's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 85 | Malte Peters | www.hookipapharma.com |
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company’s immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial.
HOOKIPA Pharma Inc. Fundamentals Summary
| HOOK fundamental statistics | |
|---|---|
| Market cap | US$15.30m |
| Earnings (TTM) | -US$73.31m |
| Revenue (TTM) | US$9.35m |
Is HOOK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HOOK income statement (TTM) | |
|---|---|
| Revenue | US$9.35m |
| Cost of Revenue | US$59.82m |
| Gross Profit | -US$50.47m |
| Other Expenses | US$22.84m |
| Earnings | -US$73.31m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.70 |
| Gross Margin | -539.76% |
| Net Profit Margin | -784.01% |
| Debt/Equity Ratio | 0% |
How did HOOK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/17 00:59 |
| End of Day Share Price | 2026/05/15 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
HOOKIPA Pharma Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| Debjit Chattopadhyay | H.C. Wainwright & Co. |